Table 5 Demographic, treatment centre, insurance coverage and drug characteristics comparison between on-label and off-label encounters
From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States
Variable | Variable category | Off-label (%) |
|---|---|---|
Age* | 15-49 | 621 (16.2%) |
50-64 | 396 (10.4%) | |
65-74 | 432 (9.7%) | |
75+ | 187 (7.4%) | |
Ethnicity* | Caucasian | 1113 (10.3%) |
African American | 185 (13.0%) | |
Other | 95 (15.3%) | |
Unknown | 243 (14.4%) | |
Marital status | Married | 338 (11.0%) |
Other | 1293 (11.3%) | |
Unknown | 5 (10.4%) | |
Prescription drug coverage* | Medicare | 209 (9.5%) |
Medicaid | 81 (10.4%) | |
HMO/PPO | 24 (6.9%) | |
Blue Cross | 65 (15.3%) | |
Self-pay | 21 (11.0%) | |
Other | 75 (12.3%) | |
Unknown | 1161 (11.6%) | |
Census region* | Midwest | 255 (8.9%) |
South | 264 (11.4%) | |
Northeast | 1088 (12.0%) | |
West | 29 (9.0%) | |
Bed size* | 1-99 | 477 (16.2%) |
100-199 | 48 (5.7%) | |
200-299 | 315 (10.0%) | |
300-499 | 234 (9.4%) | |
500+ | 562 (10.9%) | |
Physician type* | Specialists | 751 (10.9%) |
Surgeons | 22 (5.9%) | |
Generalists | 28 (6.3%) | |
Unknown | 835 (12.1%) | |
Number of approved indications* | 1-2 | 1395 (27.6%) |
3-4 | 206 (3.1%) | |
5-7 | 34 (9.5%) | |
8+ | 1 (0.0%) | |
Date of FDA approval* | Before 1981 | 130 (3.2%) |
1981-1990 | 602 (78.7%) | |
1991-2000 | 635 (7.8%) | |
2001-2009 | 269 (16.1%) |